Literature DB >> 29758204

Association between hippuric acid and left ventricular hypertrophy in maintenance hemodialysis patients.

Teng-Hung Yu1, Wei-Hua Tang2, Yung-Chuan Lu3, Chao-Ping Wang4, Wei-Chin Hung1, Cheng-Ching Wu1, I-Ting Tsai5, Fu-Mei Chung1, Jer-Yiing Houng6, Wen-Chun Lan7, Yau-Jiunn Lee8.   

Abstract

BACKGROUND: Left ventricular hypertrophy (LVH) is one of the most common cardiac abnormalities in patients with end-stage renal disease. Hippuric acid (HA), a harmful uremic toxin, is known to be elevated in patients with uremia, and serum HA levels are associated with neurological symptoms, metabolic acidosis, and accelerated renal damage associated with chronic kidney disease. However, the pathophysiological role of HA in patients with uremia remains unclear. We investigated the association between serum HA levels and echocardiographic measurements in patients undergoing hemodialysis (HD) treatment.
METHODS: Eighty consecutive patients treated at a single HD center (44 males, 36 females; mean age 66 y, mean HD duration 6 y) were included in this study. Comprehensive echocardiography was performed after HD. Blood samples were obtained before HD.
RESULTS: Pearson's correlation analysis revealed that serum HA levels were positively correlated with diastolic blood pressure, serum creatinine, left ventricular mass index, end diastolic interventricular septal thickness, left ventricular end-diastolic diameter, left ventricular end systolic diameter, end systolic left ventricular posterior wall thickness, and left atrium diameter, and negatively correlated with age. Furthermore, the HD patients with LVH had higher median serum HA levels than those without LVH (34.2 vs. 18.1 μg/ml, p = 0.003). Multiple logistic regression analysis revealed that HA was independently associated with LVH even after adjusting for known biomarkers. Moreover, the receiver operator characteristics curve of HA showed that a HA level of >26.9 μg/ml was associated with LVH.
CONCLUSIONS: HA was significantly associated with LVH. HA could be a novel biomarker of left ventricular overload, which is closely associated with an increased risk of death in HD patients.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Hemodialysis; Hippuric acid; Left ventricular hypertrophy; Uremic toxin

Mesh:

Substances:

Year:  2018        PMID: 29758204     DOI: 10.1016/j.cca.2018.05.022

Source DB:  PubMed          Journal:  Clin Chim Acta        ISSN: 0009-8981            Impact factor:   3.786


  8 in total

Review 1.  Molecular Probes, Chemosensors, and Nanosensors for Optical Detection of Biorelevant Molecules and Ions in Aqueous Media and Biofluids.

Authors:  Joana Krämer; Rui Kang; Laura M Grimm; Luisa De Cola; Pierre Picchetti; Frank Biedermann
Journal:  Chem Rev       Date:  2022-01-07       Impact factor: 60.622

Review 2.  Uremic Toxins and Cardiovascular Risk in Chronic Kidney Disease: What Have We Learned Recently beyond the Past Findings?

Authors:  Carolla El Chamieh; Sophie Liabeuf; Ziad Massy
Journal:  Toxins (Basel)       Date:  2022-04-14       Impact factor: 5.075

3.  Non-Targeted Metabolomic Profiling of Coronary Heart Disease Patients With Taohong Siwu Decoction Treatment.

Authors:  Tianqi Tao; Tao He; Huimin Mao; Xudong Wu; Xiuhua Liu
Journal:  Front Pharmacol       Date:  2020-05-08       Impact factor: 5.810

4.  Gut-Derived Metabolite Indole-3-Propionic Acid Modulates Mitochondrial Function in Cardiomyocytes and Alters Cardiac Function.

Authors:  Maren Gesper; Alena B H Nonnast; Nina Kumowski; Robert Stoehr; Katharina Schuett; Nikolaus Marx; Ben A Kappel
Journal:  Front Med (Lausanne)       Date:  2021-03-22

5.  Metabolic Evaluation of Urine from Patients Diagnosed with High Grade (HG) Bladder Cancer by SPME-LC-MS Method.

Authors:  Kamil Łuczykowski; Natalia Warmuzińska; Sylwia Operacz; Iga Stryjak; Joanna Bogusiewicz; Julia Jacyna; Renata Wawrzyniak; Wiktoria Struck-Lewicka; Michał J Markuszewski; Barbara Bojko
Journal:  Molecules       Date:  2021-04-11       Impact factor: 4.411

Review 6.  Uremic Toxins in the Progression of Chronic Kidney Disease and Cardiovascular Disease: Mechanisms and Therapeutic Targets.

Authors:  Yong Jin Lim; Nicole A Sidor; Nicholas C Tonial; Adrian Che; Bradley L Urquhart
Journal:  Toxins (Basel)       Date:  2021-02-13       Impact factor: 4.546

7.  The Lower Limit of Reference of Urinary Albumin/Creatinine Ratio and the Risk of Chronic Kidney Disease Progression in Patients With Type 2 Diabetes Mellitus.

Authors:  Wei-Hua Tang; Wei-Chin Hung; Chao-Ping Wang; Cheng-Ching Wu; Chin-Feng Hsuan; Teng-Hung Yu; Chia-Chang Hsu; Ya-Ai Cheng; Fu-Mei Chung; Yau-Jiunn Lee; Yung-Chuan Lu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-02       Impact factor: 6.055

8.  Lipidomic and Metabolomic Signature of Progression of Chronic Kidney Disease in Patients with Severe Obesity.

Authors:  Borja Lanzon; Marina Martin-Taboada; Victor Castro-Alves; Rocio Vila-Bedmar; Ignacio González de Pablos; Daniel Duberg; Pilar Gomez; Elias Rodriguez; Matej Orešič; Tuulia Hyötyläinen; Enrique Morales; Francisco J Ruperez; Gema Medina-Gomez
Journal:  Metabolites       Date:  2021-12-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.